Ph 3 KANDLELIT-007 Trial of Calderasib (MK-1084) + KEYTRUDA QLEX Initiated in Certain Patients With Advanced NSCLC
“While outcomes for patients with NSCLC have significantly improved over the last decade, we know there is more work to do. KRAS is the most frequently mutated oncogene in cancer, and the KRAS G12C mutation occurs in approximately 4% to 14% of all patients with lung cancer globally,” said Dr. Gregory Lubiniecki, vice president, global clinical development, Merck Research Laboratories. “By pairing our oral calderasib candidate with subcutaneously administered KEYTRUDA QLEX in this trial, we will evaluate whether this chemotherapy-free combination that requires no intravenous access may help improve outcomes for patients with KRAS G12C-mutant NSCLC.”
Share:
More News
Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20
“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of
“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence
“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib